Multinational phase IIb study of adavosertib for recurrent or persistent uterine serous carcinoma

The multinational phase IIb ADAGIO study evaluated the selective Wee1 inhibitor adavosertib (AZD1775) for recurrent or persistent uterine serous carcinoma (UCS) after platinum-based chemotherapy. Adavosertib was administered orally at 300 mg once daily on days 1-5 and 8-12 of 21-days cycles. The objective response rate was 26.0% (95% CI 17.9-35.5) with median duration of response 4.7 months (3.8-8.3), median progression-free survival 2.8 months (2.6-3.9) and median overall survival 9.6 months (8.3-NC). Most patients (97.2%) experienced treatment-related adverse events, with grade ≥ TRAEs in 60.6% and TRAEs leading to discontinuation in 14.7%. The authors conclude that adavosertib had some antitumor activity in patients with recurrent or persistent USC, but was not well tolerated at 300 mg once daily dosing.